US NCI (National Cancer Institute) completes lung cancer trial enrolment:
This article was originally published in Clinica
Executive Summary
The National Cancer Institute has enrolled the hoped-for 50,000 persons into the National Lung Screening Trial to test whether early screening can reduce deaths from lung cancer. The participants - all current and former smokers with no apparent symptoms of lung cancer - will be screened with either spiral computed tomography or chest X-ray once a year for three years, and then be contacted annually until 2009. Although the full complement of participants has been enrolled, the trial will remain open at selected sites to collect blood, urine and sputum to help doctors identify biomarkers of lung cancer, said the research institute, which is working in partnership with the American Cancer Society.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.